If your physician uses ocular photodynamic therapy with verteporfin for patients with eye problems, you should encourage him or her to stand up for Medicare reimbursement for this service.
The Medicare Coverage Advisory Committee will meet on Sept. 9, according to a notice in the July 25 Federal Register (Vol. 68, No. 143). The committee will consider OPT with verteporfin for Medicare patients with age-related macular degeneration and occult without any classic choroidal neovascularization. You have until Aug. 21 to submit presentations by e-mailing matkinson@cms.hhs.gov or phoning (410) 786-2881.